BLECH ISAAC 4
4 · X4 Pharmaceuticals, Inc · Filed Mar 14, 2019
Insider Transaction Report
Form 4
BLECH ISAAC
Director
Transactions
- Award
Stock Option (right to buy)
2019-03-13+70,796→ 70,796 totalExercise: $6.84Exp: 2025-12-14→ Common Stock (70,796 underlying)
Footnotes (2)
- [F1]Fully vested.
- [F2]Reflects the Reporting Person's stock option to acquire 744,967 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").